{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:45:07Z","timestamp":1774550707309,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T00:00:00Z","timestamp":1596672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Nordic University","award":["#85352"],"award-info":[{"award-number":["#85352"]}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201806350247"],"award-info":[{"award-number":["201806350247"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ejpb.2020.07.029","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T12:35:11Z","timestamp":1596630911000},"page":"22-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Functionalised calcium carbonate as a coformer to stabilize amorphous drugs by mechanochemical activation"],"prefix":"10.1016","volume":"155","author":[{"given":"Jingwen","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingunn","family":"Tho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Ofosu","family":"Kissi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2020.07.029_b0005","series-title":"Drug-Like Properties","first-page":"95","article-title":"Chapter 8 - Permeability","author":"Di","year":"2016"},{"key":"10.1016\/j.ejpb.2020.07.029_b0010","series-title":"Drug-Like Properties","first-page":"61","article-title":"Chapter 7 - Solubility","author":"Di","year":"2016"},{"key":"10.1016\/j.ejpb.2020.07.029_b0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2020.07.029_b0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2020.07.029_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.119009","article-title":"Sink conditions do not guarantee the absence of saturation effects","volume":"577","author":"Siepmann","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0030","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1016\/j.ddtec.2011.10.002","article-title":"The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate","volume":"9","author":"Van den Mooter","year":"2012","journal-title":"Drug Discov. Today: Technol."},{"key":"10.1016\/j.ejpb.2020.07.029_b0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0939-6411(00)00076-X","article-title":"Improving drug solubility for oral delivery using solid dispersions","volume":"50","author":"Leuner","year":"2000","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0040","series-title":"FASTtrack Pharmaceutics: Drug Delivery and Targeting","author":"Perrie","year":"2012"},{"key":"10.1016\/j.ejpb.2020.07.029_b0045","series-title":"Amorphous Solid Dispersions: Theory and Practice","first-page":"3","article-title":"Fundamentals of Amorphous Systems: Thermodynamic Aspects","author":"Bellantone","year":"2014"},{"key":"10.1016\/j.ejpb.2020.07.029_b0050","series-title":"Remington: The Science and Practice of Pharmacy","first-page":"117","article-title":"Molecular Structure, Properties, and States of Matter","author":"Rades","year":"2013"},{"key":"10.1016\/j.ejpb.2020.07.029_b0055","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1021\/acs.jpcb.7b10105","article-title":"Glass-transition temperature of the beta-relaxation as the major predictive parameter for recrystallization of neat amorphous drugs","volume":"122","author":"Kissi","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejpb.2020.07.029_b0060","series-title":"Amorphous Drugs: Benefits and Challenges","first-page":"107","article-title":"Physical Instability: A Key Problem of Amorphous Drugs","author":"Rams-Baron","year":"2018"},{"key":"10.1016\/j.ejpb.2020.07.029_b0065","series-title":"Amorphous Solid Dispersions: Theory and Practice","first-page":"35","article-title":"Theoretical Considerations in Developing Amorphous Solid Dispersions","author":"Laitinen","year":"2014"},{"key":"10.1016\/j.ejpb.2020.07.029_b0070","series-title":"Amorphous Solid Dispersions: Theory and Practice","first-page":"123","article-title":"Excipients for Amorphous Solid Dispersions","author":"Vaka","year":"2014"},{"key":"10.1016\/j.ejpb.2020.07.029_b0075","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.addr.2015.12.009","article-title":"Recent advances in co-amorphous drug formulations","volume":"100","author":"Dengale","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2020.07.029_b0080","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijpharm.2018.12.080","article-title":"Lipids and polymers in pharmaceutical technology: Lifelong companions","volume":"558","author":"Siepmann","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0085","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","article-title":"Polymeric amorphous solid dispersions: A review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs","volume":"105","author":"Baghel","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.07.029_b0090","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1007\/s11095-006-9063-9","article-title":"Theoretical and practical approaches for prediction of drug\u2013polymer miscibility and solubility","volume":"23","author":"Marsac","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2020.07.029_b0095","doi-asserted-by":"crossref","first-page":"372","DOI":"10.3390\/pharmaceutics11080372","article-title":"Analytical and computational methods for the estimation of drug-polymer solubility and miscibility in solid dispersions development","volume":"11","author":"Medarevi\u0107","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.07.029_b0100","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ejpb.2013.03.014","article-title":"Amino acids as co-amorphous stabilizers for poorly water soluble drugs \u2013 Part 1: Preparation, stability and dissolution enhancement","volume":"85","author":"L\u00f6bmann","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejpb.2018.07.016","article-title":"Organic acids as co-formers for co-amorphous systems \u2013 Influence of variation in molar ratio on the physicochemical properties of the co-amorphous systems","volume":"131","author":"Wu","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0110","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ejpb.2018.11.016","article-title":"Dipeptides as co-formers in co-amorphous systems","volume":"134","author":"Wu","year":"2019","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijpharm.2012.04.066","article-title":"Emerging trends in the stabilization of amorphous drugs","volume":"453","author":"Laitinen","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0120","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/mp2002973","article-title":"Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen","volume":"8","author":"L\u00f6bmann","year":"2011","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.07.029_b0125","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11120628","article-title":"Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures","volume":"11","author":"Kissi","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.07.029_b0130","series-title":"Amorphous Solid Dispersions: Theory and Practice","first-page":"613","article-title":"Stabilized Amorphous Solid Dispersions with Small Molecule Excipients","author":"L\u00f6bmann","year":"2014"},{"key":"10.1016\/j.ejpb.2020.07.029_b0135","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1021\/acs.molpharmaceut.8b00650","article-title":"The role of glass transition temperatures in coamorphous drug-amino acid formulations","volume":"15","author":"Kissi","year":"2018","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.07.029_b0140","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ijpharm.2017.10.057","article-title":"On the role of salt formation and structural similarity of co-formers in co-amorphous drug delivery systems","volume":"535","author":"Wu","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0145","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/pharmaceutics10040279","article-title":"Mesoporous silica materials as drug delivery: \u201cThe nightmare\u201d of bacterial infection","volume":"10","author":"Mart\u00ednez-Carmona","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.07.029_b0150","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/jps.22779","article-title":"Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery systems","volume":"101","author":"Qian","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.07.029_b0155","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3390\/pharmaceutics10040167","article-title":"Porous inorganic carriers based on silica, calcium carbonate and calcium phosphate for controlled\/modulated drug delivery: Fresh outlook and future perspectives","volume":"10","author":"Trofimov","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.07.029_b0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/pharmaceutics11010032","article-title":"Loading of porous functionalized calcium carbonate microparticles: Distribution analysis with focused ion beam electron microscopy and mercury porosimetry","volume":"11","author":"Farzan","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.07.029_b0165","series-title":"Amorphous Solid Dispersions: Theory and Practice","first-page":"665","article-title":"Mesoporous silica drug delivery systems","author":"Choudhari","year":"2014"},{"key":"10.1016\/j.ejpb.2020.07.029_b0170","doi-asserted-by":"crossref","first-page":"19686","DOI":"10.1039\/C9CP01764J","article-title":"Characterising glass transition temperatures and glass dynamics in mesoporous silica-based amorphous drugs","volume":"21","author":"Kissi","year":"2019","journal-title":"Phys. Chem. Chem. Phys."},{"key":"10.1016\/j.ejpb.2020.07.029_b0175","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.colsurfa.2003.12.030","article-title":"Modified calcium carbonate coatings with rapid absorption and extensive liquid uptake capacity","volume":"236","author":"Ridgway","year":"2004","journal-title":"Colloids Suf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.ejpb.2020.07.029_b0180","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejpb.2017.10.012","article-title":"Functionalized calcium carbonate microparticles for the delivery of proteins","volume":"122","author":"Roth","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0185","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s11095-013-1034-3","article-title":"Functionalized calcium carbonate as a novel pharmaceutical excipient for the preparation of orally dispersible tablets","volume":"30","author":"Stirnimann","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2020.07.029_b0190","series-title":"Amorphous Solid Dispersions: Theory and Practice","first-page":"91","article-title":"Overview of Amorphous Solid Dispersion Technologies","author":"Sandhu","year":"2014"},{"key":"10.1016\/j.ejpb.2020.07.029_b0195","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1002\/jps.22519","article-title":"Spontaneous crystalline-to-amorphous phase transformation of organic or medicinal compounds in the presence of porous media, part 1: thermodynamics of spontaneous amorphization","volume":"100","author":"Qian","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.07.029_b0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejpb.2008.06.022","article-title":"Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation","volume":"71","author":"Chieng","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0205","first-page":"1179","article-title":"A standardized mini paddle apparatus as an alternative to the standard paddle","volume":"9","author":"Klein","year":"2008","journal-title":"AAPS Pharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0210","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejps.2016.08.022","article-title":"Development of a screening method for co-amorphous formulations of drugs and amino acids","volume":"95","author":"Kasten","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2020.07.029_b0215","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1021\/acs.molpharmaceut.6b00650","article-title":"Glass forming ability of amorphous drugs investigated by continuous cooling and isothermal transformation","volume":"13","author":"Blaabjerg","year":"2016","journal-title":"Mol. Pharmaceutics"},{"key":"10.1016\/j.ejpb.2020.07.029_b0220","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijpharm.2018.04.035","article-title":"A fast and reliable DSC-based method to determine the monomolecular loading capacity of drugs with good glass-forming ability in mesoporous silica","volume":"544","author":"Hempel","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0225","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ijpharm.2010.12.035","article-title":"Carvedilol dissolution improvement by preparation of solid dispersions with porous silica","volume":"406","author":"Planin\u0161ek","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2020.07.029_b0230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.powtec.2006.05.012","article-title":"Development, characterization and stabilization of amorphous form of a low Tg drug","volume":"167","author":"Pokharkar","year":"2006","journal-title":"Powder Technol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120302320?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641120302320?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:37:33Z","timestamp":1760546253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641120302320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":46,"alternative-id":["S0939641120302320"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.07.029","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functionalised calcium carbonate as a coformer to stabilize amorphous drugs by mechanochemical activation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2020.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}